Featured Content
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Myeloma News
Belantamab Mafodotin Deemed Safe, Effective in Real-World MM Population
Source: Myeloma - Hematology Advisor Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma. Read More
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study
Source: Myeloma : nature.com subject feeds Post Content Read More
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
Source: Myeloma : nature.com subject feeds Post Content Read More
Exercise App Appears Supportive, Responsive for Patients With Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine whether a novel exercise app would be helpful for patients with multiple myeloma. Read More
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Source: Myeloma : nature.com subject feeds Post Content Read More
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
Source: Myeloma : nature.com subject feeds Post Content Read More
Motixafortide Plus G-CSF Increases HSPC Numbers for Apheresis Prior to ASCT
Source: Myeloma - Hematology Advisor A phase 3, randomized study compared motixafortide with placebo to determine safety and efficacy of the drug in the mobilization of CD34+ HSPCs in patients with MM. Read More
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Source: Myeloma : nature.com subject feeds Post Content Read More
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
Source: Myeloma : nature.com subject feeds Post Content Read More
Recent Publications
Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA
Future Oncol. 2023 Jun 7. doi: 10.2217/fon-2023-0020. Online ahead of print. ABSTRACT Aim: To explore treatment selection for relapsed/refractory multiple myeloma (RRMM), which remains complex due to heterogeneity of available treatments and lack of defined standard...
Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma
Support Care Cancer. 2023 Jun 6;31(7):379. doi: 10.1007/s00520-023-07835-y. ABSTRACT PURPOSE: Verify the association between anticholinergic burden and health-related quality of life of patients with multiple myeloma. METHODS: Cross-sectional study with multiple...
Cyclical 10-day dosing of melphalan for canine multiple myeloma
Vet Comp Oncol. 2023 Jun 5. doi: 10.1111/vco.12916. Online ahead of print. ABSTRACT Canine multiple myeloma (MM) is typically treated with melphalan chemotherapy. A protocol with repeated 10-day cyclical dosing of melphalan has been used at our institution but has not...
Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231177678. doi: 10.1177/10760296231177678. ABSTRACT Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the...
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
J Hematol Oncol. 2023 Jun 5;16(1):60. doi: 10.1186/s13045-023-01461-1. ABSTRACT B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression...
Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease
J Bone Miner Res. 2023 Jun 5. doi: 10.1002/jbmr.4863. Online ahead of print. NO ABSTRACT PMID:37277117 | DOI:10.1002/jbmr.4863
Cutaneous secondary localization of multiple myeloma at Heparin injection sites
Skin Health Dis. 2023 Feb 2;3(3):e153. doi: 10.1002/ski2.153. eCollection 2023 Jun. ABSTRACT We report two cases of multiple myeloma skin localizations at Heparin injections sites in patients followed at the University Hospital of Martinique. These skin manifestations...
Therapeutic strategies to enhance immune response induced by multiple myeloma cells
Front Immunol. 2023 May 18;14:1169541. doi: 10.3389/fimmu.2023.1169541. eCollection 2023. ABSTRACT Multiple myeloma (MM)as a haematological malignancy is still incurable. In addition to the presence of somatic genetic mutations in myeloma patients, the presence of...
